Following the news on March 19, 2019 that Merck KGaA and Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian PARP 100 study for previously untreated advanced ovarian cancer,
Paul Jeng, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on Talzenna (talazoparib) in ovarian cancer:
"The combination of Bavencio and Talzenna has seen a steady erosion of its prospects in ovarian cancer since the JAVELIN Ovarian PARP 100 study was initiated less than a year ago. Merck & Co. and AstraZeneca"™s Lynparza has widened its lead over other PARP inhibitors in ovarian cancer with an approval as first-line maintenance therapy, while Pfizer"™s Talzenna remains the only drug in its class that has yet to authorized for this indication.
"Merck KGaA and Pfizer have the option to initiate another Phase III Talzenna combination study using Lynparza as a new comparator. However, it may be more advantageous for the developers to cut their losses and reorient to other indications. Bavencio has already faced clinical failures in advanced ovarian cancer, missing the mark in two late-stage trials in late 2018.
"Talzenna is currently approved for treatment of patients with BRCA-mutated, HER2-negative breast cancer, and experts believe it has the potential to be a best-in-class breast cancer drug on the basis of its potent, single-pill oral regimen. Pfizer"™s best chances for success will be to continue development of Talzenna in patients with breast cancer or gain a foothold in metastatic castration-resistant prostate cancer, where it is currently being assessed in combination with enzalutamide."
ENDS
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
GlobalData.com | LinkedIn | Twitter
– Information based on GlobalData"™s report: PARP Inhibitors in Oncology
– Include any relevant further information here, such as definitions, clarifications or research scopes
– Comments provided by Paul Jeng, PhD, Healthcare Analyst at GlobalData
About GlobalData
4,000 of the world"™s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData"™s unique data, expert analysis and innovative solutions, all in one platform. GlobalData"™s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.